<DOC>
	<DOCNO>NCT00117624</DOCNO>
	<brief_summary>The purpose study compare efficacy darbepoetin alfa administer use front-loading approach subject receive standard weekly dosing treatment anemia subject non-myeloid malignancy receive multicycle chemotherapy .</brief_summary>
	<brief_title>A Study Darbepoetin Alfa Treatment Anemia Subjects With Non-Myeloid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Nonmyeloid malignancy At least 12 additional week cyclic cytotoxic chemotherapy anticipate regardless schedule ECOG 02 Cancer and/or chemotherapyassociated anemia Known history seizure disorder Known primary hematologic disorder , could cause anemia , nonmyeloid malignancy Unstable uncontrolled disease/condition , related affect cardiac function Clinically significant inflammatory disease Inadequate renal and/or liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>